The Medicines Control Council has withdrawn the diabetes medicine Avandia from the market because it contains a substance that might increase the likelihood of a heart attack.The medication, produced by GlaxoSmithKline, is prescribed to some type2 diabetics.The council made the decision five weeks ago "due to safety risks" attributed to rosiglitazone, a constituent of Avandia. A statement by the council on Tuesday said: "Rosiglitazone is associated with an increased risk [of] heart failure, myocardial infarction [heart attack] and cardiac arrest".
